Eugene Zhukovsky

Chief Scientific Officer at Ichnos Sciences

Eugene Zhukovsky, Ph.D. is a renowned expert in the field of biotechnology, with over 25 years of international experience in the research and development of novel immuno-oncology therapies. His background includes work in discovery, antibody engineering and translational sciences, and he has successfully built drug discovery platforms.

In addition to Dr. Zhukovsky’s scientific expertise, he has demonstrated extensive leadership skills while serving as an executive at several biopharmaceutical companies and he was a major contributor to the development of a product approved for a hematologic malignancy. Prior to joining Ichnos Sciences, Dr. Zhukovsky was the CSO at Affimed, where he led the advancement of candidates from discovery through clinical development. As the Chief Technology Officer at Go Therapeutics, he created a T Cell Engagement platform to enable the leveraging of the company’s unique cancer cell-targeting antibodies. He also served as the CSO at Biomunex Pharmaceuticals, where he focused on immuno-oncology and T cell engagers based on their bispecific antibody platform.

Dr. Zhukovsky was a co-founder and partner at ZM Scientific, and he has published extensively in scientific journals. He is listed as a co-inventor of more than 15 granted patents and patent applications, including several related to the optimization of antibodies targeting CD3, CD19, CD33, and CD40. Dr. Zhukovsky earned a Ph.D. in Biochemistry from Brandeis University and was a postdoctoral fellow at Genentech.

Links

Previous companies

Boehringer Ingelheim logo
Affimed logo
GO Therapeutics logo
Xencor logo

Timeline

  • Chief Scientific Officer

    March, 2022 - present

View in org chart